New hope for pancreatic cancer: targeted antibody plus chemotherapy enters phase 3 trial

NCT ID NCT07383922

Not yet recruiting Disease control Sponsor: FutureGen Biopharmaceutical (Beijing) Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether adding the experimental antibody FG-M108 to standard chemotherapy (gemcitabine and nab-paclitaxel) helps people with advanced pancreatic cancer live longer. About 524 participants with Claudin18.2-positive tumors will be randomly assigned to receive either the antibody or a placebo, plus chemo. The study is not yet recruiting and aims to find a more effective first-line treatment for this aggressive cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FG-M108 (a monoclonal antibody) combined with gemcitabine and nab-paclitaxel chemotherapy
What this could lead to: If successful, this could provide a new first-line treatment option for advanced pancreatic cancer, potentially extending survival for patients with Claudin18.2-positive tumors.
What could go wrong: This is an early-stage Phase 3 trial, so results are not guaranteed. The drug may not improve survival or could cause additional side effects when combined with chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Fudan University Shanghai Cancer Center

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.